TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Camperdown, New South Wales, Australia
Withdrawn - Novartis Investigative Site
Wollongong, New South Wales, Australia
Recruiting
- Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
- Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
- Novartis Investigative Site
Guangzhou, China
Recruiting
- Novartis Investigative Site
Créteil, France
Recruiting - Novartis Investigative Site
Lille, France
Recruiting - Novartis Investigative Site
Nantes, France
Recruiting
- Novartis Investigative Site
Jena, Thuringia, Germany
Recruiting - Novartis Investigative Site
Essen, Germany
Recruiting
- Novartis Investigative Site
Hong Kong, Hong Kong
Recruiting
- Novartis Investigative Site
Budapest, Hungary
Recruiting - Novartis Investigative Site
Budapest, Hungary
Recruiting - Novartis Investigative Site
Szeged, Hungary
Recruiting
- Novartis Investigative Site
Rozzano, MI, Italy
Recruiting - Novartis Investigative Site
Verona, VR, Italy
Recruiting
- Novartis Investigative Site
Seoul, South Korea
Recruiting - Novartis Investigative Site
Seoul, South Korea
Recruiting
- Novartis Investigative Site
Madrid, Spain
Recruiting - Novartis Investigative Site
Madrid, Spain
Recruiting - Novartis Investigative Site
Madrid, Spain
Recruiting
- Novartis Investigative Site
Ankara, Sihhiye-Altindag, Turkey (Türkiye)
Recruiting
- Novartis Investigative Site
London, United Kingdom
Recruiting
- Univ of Alabama at Birmingham
Birmingham, Alabama, United States
Joelle HamiltonRecruiting - Uni of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Fernando Maciel BarbosaRecruiting - University of Kansas Cancer Center
Westwood, Kansas, United States
Haoran LiRecruiting - Wichita Urology Group Pa
Wichita, Kansas, United States
Timothy RichardsonRecruiting - Duke University Medical Center
Durham, North Carolina, United States
Jeffrey ShevachRecruiting - Medical University of South Carolina Musc
Charleston, South Carolina, United States
Kevin BeckerRecruiting - Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Neal ShoreRecruiting - Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Jan 2026
- Primary completion
- 2 Aug 2032
- Completion
- 2 Aug 2032
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 181
- Registry id
- NCT07190300
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.